Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd155-hIi-HBV
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
ChAd155-hIi-HBV is a recombinant, replication-defective simian (chimpanzee-derived) group C adenovirus serotype 155 (ChAd155) viral vector-based DNA vaccine developed for the treatment of chronic hepatitis B. The vector encodes a fusion protein comprising two hepatitis B virus (HBV) antigens: a truncated core nucleocapsid protein antigen (HBc) and the full-length small surface antigen (HBs), separated by a self-cleaving 2A region from foot-and-mouth disease virus to allow processing into separate proteins. Additionally, the N-terminal part of the gene encoding HBc is fused to human MHC class II-associated invariant chain p35 isoform (hIi), which enhances T-cell responses. The vaccine is administered intramuscularly and aims to stimulate both humoral and cellular immune responses against HBV antigens as an immunostimulant therapeutic approach for chronic hepatitis B[1][2][3][5][6].
- Other names
- Recombinant chimpanzee adenovirus type 155 HBV vaccineChimpanzee adenovirus HBV vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on ChAd155-hIi-HBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd155-hIi-HBV.